DATROWAY AstraZeneca Pty Ltd
Product name
DATROWAY
Sponsor
Accepted date
May-2024
Active ingredients
datopotamab deruxtecan
Proposed indication
For the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy.
Application type
A (new medicine)
Publication date
May-2024